Ultrafast CT developer Imatron last week reported a $2.4 millionnet loss and sharply lower revenues for 1995 (end-December), butstruck an optimistic stance due to promising clinical resultsbeing reported on its technology. The South San Francisco,
Ultrafast CT developer Imatron last week reported a $2.4 millionnet loss and sharply lower revenues for 1995 (end-December), butstruck an optimistic stance due to promising clinical resultsbeing reported on its technology. The South San Francisco, CA,vendor said that the lower results were due to increased expensesrelated to the start-up of its HeartScan Imaging subsidiary, aswell as delays in securing orders in the Far East.
Imatron reported revenues for the year of $26.7 million, downfrom $33.6 million in 1994. The company's $2.4 million net lossfor 1995 compares with net income of $2.3 million in 1994.
For the fourth quarter, Imatron posted a net loss of $2.2 millionon revenues of $7 million, compared with net income of $700,000on sales of $10.8 million in the fourth quarter of 1994.
Imatron said the loss was attributable to expenses relatedto the building of a national network of HeartScan Imaging centers,which will provide coronary artery disease (CAD) screening directlyto the public, using Imatron's ultrafast CT scanners. Imatronopened centers in Houston and Seattle last year and laid the groundworkfor new centers in Washington, DC, and Pittsburgh.
Scanner sales were negatively affected by problems securingletters of credit from foreign banks. Two orders to China havebeen delayed, and others put on hold, Imatron said.
On the positive side, the company has been receiving mediaattention based on clinical reports of the utility of its technologyin detecting early signs of CAD (SCAN3/13/96). Imatron believesthat these studies will lay the foundation for increased consumerdemand for ultrafast CT CAD screening to be provided by HeartScancenters.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.